Trial reportBMC oral health2025
The effect of Polyvinylpyrrolidone-Sodium hyaluronate gel on palatal wound healing: a randomized controlled clinical trial.
Trial report in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06610331 (EVALUATION OF THE EFFECT OF POLYVINYLPYROLIDONE AND SODIUM HYALURONATE GEL ON PALATINAL WOUND HEALING), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the effect of polyvinylpyrolidone and sodium hyaluronate gel on palatinal wound healing: a randomized controlled clinical study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundThis study evaluates the effect of polyvinylpyrrolidone sodium hyaluronate gel (Gelclair
methodsThirty-two patients undergoing FGG were randomly assigned to two groups: the test group received Gelclair
resultsH₂O₂ test values significantly decreased and WHI values significantly increased over time in both groups (p < 0.050). Test and control groups comparison at time points showed the test group showed significantly lower H₂O₂ test values on days 7, 14, and 28 (p < 0.050) and higher WHI values on days 3, 7, 14, and 28 compared to control group. VAS pain, chewing, and burning scores were also significantly lower in the test group on days 1, 3, 7, and 14 compared to control. While on day 1, the control group had a bleeding rate of 105 times higher than the test group (p < 0.001), no significant differences were observed on days 3 and 7.
conclusionsThe findings suggest that Gelclair TRIAL REGISTRATION NUMBER: NCT06610331; Retrospectively registered on 23/09/2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.